These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25697878)

  • 1. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review.
    Aguiar CL; Pan N; Adams A; Barinstein L; Lehman TJ
    Clin Rheumatol; 2015 Oct; 34(10):1821-4. PubMed ID: 25697878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis.
    Hügle B; Speth F; Haas JP
    Pediatr Rheumatol Online J; 2017 Mar; 15(1):16. PubMed ID: 28288653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
    Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
    Atemnkeng Ntam V; Klein A; Horneff G
    Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
    [No Abstract]   [Full Text] [Related]  

  • 6. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab.
    Epçaçan S; Sahin S; Kasapcopur O
    Cardiol Young; 2019 Apr; 29(4):549-551. PubMed ID: 30931868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
    Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
    Toplak N; Blazina Š; Avčin T
    Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Orrock JE; Ilowite NT
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
    Martins FR; Azevedo AC; Ganhão S; Aguiar F; Rodrigues M; Brito I
    Pediatr Rheumatol Online J; 2023 Oct; 21(1):112. PubMed ID: 37803456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab for the treatment of systemic juvenile idiopathic arthritis.
    Grom AA
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
    Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
    Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
    Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
    Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
    Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.
    Sun H; Van LM; Floch D; Jiang X; Klein UR; Abrams K; Sunkara G
    J Clin Pharmacol; 2016 Dec; 56(12):1516-1527. PubMed ID: 27119439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
    Swart JF; Barug D; Möhlmann M; Wulffraat NM
    Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
    Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
    Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
    Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
    Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
    Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
    J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.